The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
Open accessAbstract
Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune microenvironment. Ionizing radiation (IR)-induced DNA damage repair (DDR) pathway activation leads to the inhibition of immune microenvironment, thus impairing the antitumor effect of radioimmunotherapy. However, it is unclear whether inhibition of the DDR pathway can enhance the effect of radioimmunotherapy. In this study, we aim to explore the role of DDR inhibitor AZD6738 on the combination of radiotherapy and immune checkpoint inhibitors (ICIs) in HCC. Methods C57BL/6 mouse subcutaneous tumor model was used to evaluate the ability of different treatment regimens in tumor growth control and tumor recurrence inhibition. Effects of each treatment regimen on the alterations of immunophenotypes including the quantification, activation, proliferating ability, exhaustion marker expression, and memory status were assessed by flow cytometry. Results AZD6738 further increased radiotherapy-stimulated CD8 + T cell infiltration and activation and reverted the immunosuppressive effect of radiation on the number of Tregs in mice xenografts. Moreover, compared with radioimmunotherapy (radiotherapy plus anti-PD-L1 (Programmed death ligand 1)), the addition of AZD6738 boosted the infiltration, increased cell proliferation, enhanced interferon (IFN)-γ production ability of TIL (tumor-infiltrating lymphocyte) CD8 + T cells, and caused a decreasing trend in the number of TIL Tregs and exhausted T cells in mice xenografts. Thus, the tumor immune microenvironment was significantly improved. Meanwhile, triple therapy (AZD6738 plus radiotherapy plus anti-PD-L1) also induced a better immunophenotype than radioimmunotherapy in mice spleens. As a consequence, triple therapy displayed greater benefit in antitumor efficacy and mice survival than radioimmunotherapy. Mechanism study revealed that the synergistic antitumor effect of AZD6738 with radioimmunotherapy relied on the activation of cyclic GMP–AMP synthase /stimulator of interferon genes (cGAS/STING) signaling pathway. Furthermore, triple therapy led to stronger immunologic memory and lasting antitumor immunity than radioimmunotherapy, thus preventing tumor recurrence in mouse models. Conclusions Our findings indicate that AZD6738 might be a potential synergistic treatment for radioimmunotherapy to control the proliferation of HCC cells, prolong survival, and prevent tumor recurrence in patients with HCC by improving the immune microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, ATR inhibitors appear to offset the ability of RT to drive PD-L1 upregulation (Vendetti et al., 2018) and hence synergize with RT and ICIs in the control of mouse hepatocellular carcinomas established in immunocompetent hosts (Sheng et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sheng et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Based on preliminary translational observations, our work raised the possibility that AZD6738 might be a potential synergistic modality for radioimmunotherapy in HCC. Remark-edly, this study provides a basis for future clinical human studies into the treatment of HCC.”
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“In summary, compared with radioimmunotherapy, triple therapy can further reduce the coexpression of CD8 + T cell exhaustion markers in mice xenograft tumors and spleens.”
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · cited 1×
“7 8 There are increasing substantial preclinical studies showing that radiotherapy combined with ICIs improve the control rate and reduce the recurrence rate of multiple types of cancers, including HCC. 9 Therefore, it appears that the combination of radiotherapy and ICIs may become a promising…”
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · cited 1×
“11 14 However, other than simulative effect, radiation also has suppressive effect on the tumor environment.”
Cited by
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer
Storozynsky, Q., & Hitt, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 228
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 213
DNA repair defects in cancer and therapeutic opportunities
Hopkins, J. L., Lan, L., & Zou, L. (2022) · Genes & Development · doi:10.1101/gad.349431.122 · Cited by 200
“ATRi also enhances the radiation-induced inflammatory tumor microenvironment (Dillon et al. 2019; Sheng et al. 2020).”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 177
Hui, R., Özgüroğlu, M., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30519-4 · Cited by 187
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
The role of cGAS-STING signalling in liver diseases
Chen, R., Du, J., Zhu, H., & Ling, Q. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100324 · Cited by 145
“ATR inhibitors enhance the antitumor activity of radiotherapy in HCC and these effects are dependent on the activation of cGAS-STING signalling.(102) Inhibition of ATM in ARID1A (AT-rich interaction domain 1 A)deficient tumors(103) causes leakage of mtDNA or replicative stress, which activates the cytoplasmic cGAS-STI…”
BackgroundRecent advances in DDR (DNA damage response) inhibitors for cancer therapy
Cheng, B., Pan, W., Xing, Y., Xiao, Y., Chen, J., & Xu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114109 · Cited by 136
Self-citationDetection and quantification of microplastics in various types of human tumor tissues
Zhao, J., Zhang, H., Shi, L., Jia, Y., & Sheng, H. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116818 · Cited by 133
Self-citationTargeting ATR in patients with cancer
Ngoi, N. Y. L., Pilie, P. G., McGrail, D. J., Zimmermann, M., Schlacher, K., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00863-5 · Cited by 122
“In mouse models of hepatocellular cancer, these changes led to increased CD8 + T cell infiltration and antigen presentation in the tumour microenvironment, and reduced infiltration of immunosuppressive regulatory T cells, the number of exhausted T cells and TIM3 expression 99,101 .”
The DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 123
Huang, W., Zhang, L., Yang, M. Y., Wu, X., Wang, X., Huang, W., Lu, Y., Pan, H., Wang, Y., Wang, Z., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01878-x · Cited by 109
“Mice were divided into six groups as required and received irradiation treatment at a 8Gy × 3 schedule 9 days after injection [24, 25].”
MethodLiu, C., Wang, X., Qin, W., Tu, J., Li, C., Zhao, W., Ma, L., Liu, B., Qiu, H., & Yuan, X. (2023) · 癌症:英文版 · doi:10.1002/cac2.12412 · Cited by 108
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
Ngoi, N. Y. L., Pham, M. M., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.002 · Cited by 101
Interfaces between cellular responses to DNA damage and cancer immunotherapy
Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 99
A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
Zhou, X., Du, J., Liu, C., Zeng, H., Chen, Y., Liu, L., & Wu, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688215 · Cited by 104
Hardaker, E. L., Sanseviero, E., Karmokar, A., Taylor, D. K., Milo, M., Michaloglou, C., Hughes, A. M., Mai, M., King, M. A., Solanki, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45996-4 · Cited by 82
“Activation of IFNI pathway by ATRi is not surprising considering possible role of ATRi in STING activation 4,6,20 .”
Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis
Wang, Q. L., Li, S., Qiao, S., Zheng, Z., Duan, X., & Zhu, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648652 · Cited by 79
Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Opportunities
Siri, S. O., Martino, J., & Gottifredi, V. (2021) · Cancers · doi:10.3390/cancers13123056 · Cited by 83
cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
Long, Z., Wang, J., Xu, J., Lei, X., & Liu, Q. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.044 · Cited by 78
“A better immunophenotype is obtained relying on the activation of cGAS/STING signaling, and subsequently the therapeutic efficacy is enhanced.(89)”
MethodSelf-citationPatin, E. C., Dillon, M. T., Nenclares, P., Grove, L., Soliman, H., Leslie, I., Northcote, D., Bozhanova, G., Crespo-Rodriguez, E., Baldock, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004306 · Cited by 76
Emerging strategies for cancer therapy by ATR inhibitors
Yano, K., & Shiotani, B. (2023) · Cancer Science · doi:10.1111/cas.15845 · Cited by 73
Gao, Z., Xu, J., Yang, F., Zhang, Z., Wang, H., Qian, M., Zhang, P., Deng, L., Shen, J., Xue, H., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02526-8 · Cited by 71
Self-citationAdvances in radiotherapy and immunity in hepatocellular carcinoma
Yang, Y., Xiong, L., Li, M., Jiang, P., Wang, J., & Li, C. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04386-y · Cited by 71
“…activation of the cGAS/STING signalling pathway by AZD6738, which is conducive to the synergistic effect between radiotherapy and anti-PD-L1, and this triple combination therapy can generate stronger immune memory and persistent antitumour immunity, thereby preventing tumour recurrence [118].”
BackgroundSelf-citationAppleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Ono, M., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 65
“Treatment with an ATR inhibitor was shown to synergise with radiotherapy and checkpoint inhibition in a pre-clinical model of liver cancer (158).”
BackgroundNakamura, K., Karmokar, A., Farrington, P. M., James, N. H., Ramos‐Montoya, A., Bickerton, S. J., Hughes, G. D., Illidge, T., Cadogan, E. B., Davies, B. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3701 · Cited by 63
“expression can occur in response to treatment with DNA-damaging agents such as RT (24, 47), topoisomerase II inhibitors (48), and DDR inhibitors in DDR-deficient tumor cells by inducing synthetic lethality (42).”
BackgroundChen, Y., Zhou, P., Deng, Y., Cai, X., Sun, M., Sun, Y., & Wu, D. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1198 · Cited by 60
Self-citationHan, D., Zhang, J., Bao, Y., Liu, L., Wang, P., & Qian, D. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01256-2 · Cited by 67
“Flow cytometry analysis Lymphocytes were extracted from peripheral blood (PB), tumors and spleens as previously described [9, 25].”
MethodZhong, L., Wu, D., Peng, W., Sheng, H., Xiao, Y., Zhang, X., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.686621 · Cited by 56
“The initial results of combining radiotherapy with immunomodulatory agents have generated promising data in pre-clinical studies (12, 13), which has, in”
BackgroundSelf-citationHuang, Y., Sheng, H., Xiao, Y., Hu, W., Zhang, Z., Chen, Y., Zhu, Z., Wu, D., Cao, C., & Sun, J. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.034 · Cited by 52
Self-citationHak, C. C. W., Rullan, A., Patin, E. C., Pedersen, M., Melcher, A. A., & Harrington, K. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971959 · Cited by 51
“Promising preclinical in vivo studies (Table 1) of the ATR inhibitor ceralasertib (AZD6738) in combination with radiotherapy have shown an enhanced type I/II interferon response and increased immune cell infiltrate (88), increased RT-stimulated CD8+ T cell infiltration (87, 89), NK-mediated anti-tumour immunity (90),…”
BackgroundCancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage
Fernandez, A., Artola, M., Leon, S., Otegui, N., Jimeno, A., Serrano, D., & Calvo, A. (2025) · Cells · doi:10.3390/cells14100748 · Cited by 50
“In hepatocellular carcinoma, addition of the ATR targeting drug AZD6738 to radioim-munotherapy boosted the immune cell infiltration and enhanced interferon (IFN)- γ production [145].”
Advancing cancer therapy: new frontiers in targeting DNA damage response
Qian, J., Liao, G., Chen, M., Peng, R., Yan, X., Du, J., Huang, R., Pan, M., Lin, Y., Gong, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1474337 · Cited by 50
Guo, Y., Wang, J., Benedict, B., Yang, C. G., van Gemert, F. P. A., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00981-0 · Cited by 49
Self-citationPérez-Romasanta, L. A., Portillo, E. G.-D., Rodríguez-Gutierrez, A., & Matías-Pérez, Á. (2021) · Cancers · doi:10.3390/cancers13020192 · Cited by 47
“Furthermore, triple therapy led to stronger immunologic memory and lasting antitumor immunity than RT plus anti-PD-L1, thus preventing tumor recurrence [127].”
BackgroundA Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 46
Vendetti, F. P., Pandya, P., Clump, D. A., Schamus-Haynes, S., Tavakoli, M., diMayorca, M. S., Islam, N. M., Chang, J., Delgoffe, G. M., Beumer, J. H., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165615 · Cited by 41
Nucleic Acid Immunity and DNA Damage Response: New Friends and Old Foes
Taffoni, C., Steer, A., Marines, J., Chamma, H., Vila, I. K., & Laguette, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660560 · Cited by 45
“Importantly, the cGAS-STING pathway was shown to potentiate the response to radiotherapy and chemotherapy (88, 93) and to synergize with checkpoint inhibitors (94, 95).”
BackgroundWanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 43
Huang, M., Cha, Z., Liu, R., Lin, M., Gafoor, N. A., Kong, T., Ge, F., & Chen, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399926 · Cited by 47
Zhao, X., Hu, S., Zeng, L., Liu, X., Song, Y., Zhang, Y., Chen, Q., Bai, Y., Zhang, J., Zhang, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104690 · Cited by 37
“However, IR could also increase the expression of PD-L1 on the surface of tumor cells (Deng et al., 2014; Sheng et al., 2020), which could inhibit T cell activity and engender immune escape of tumor cells (Jiang et al., 2019; Peng et al., 2019), consequently may impair IR-induced ATAE.”
BackgroundDrug co-administration in the tumor immune microenvironment of Hepatocellular carcinoma
Shao, Y., Su, R., Wang, Y., Yin, S., Pu, W., Koo, S., & Yu, H. (2023) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000074 · Cited by 38
Expanding roles of cell cycle checkpoint inhibitors in radiation oncology
Hauge, S., Mariampillai, A. E., Rødland, G. E., Bay, L. T. E., Landsverk, H. B., & Syljuåsen, R. G. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1913529 · Cited by 39
“Furthermore, the ATR inhibitor AZD6738 promoted anti-tumor effects when combined with irradiation and immune checkpoint blockade in a hepatocellular carcinoma mouse model, and this was also dependent on cGAS–STING signaling (Sheng et al. 2020).”
BackgroundThe complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways
Li, D., Shao, F., Yu, Q., Wu, R., Tuo, Z., Wang, J., Ye, L., Guo, Y., Yoo, K. H., Ke, M., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01776-7 · Cited by 35
“The inhibition of the DNA damage repair pathway with AZD6738 has been shown to enhance the effectiveness of radioimmunotherapy for hepatocellular carcinoma by recruiting CD8 + T cell infiltration [140].”
BackgroundSelf-citationYuan, M., Zhai, Y., Men, Y., Zhao, M., Sun, X., Ma, Z., Bao, Y., Yang, X., Sun, S., Liu, Y., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5479491 · Cited by 36
“It can be inferred that the sensitization e ff ect of anlotinib might be more signi fi cant in hypofractionated radiotherapy [21].”
Self-citationT Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Yang, Y. P., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., & Sun, C. (2026) · Advanced Science · doi:10.1002/advs.202520634 · Cited by 34
Ma, Q., Shen, M.-O., Han, N., Xu, H., Peng, X., Li, Q., Yu, T., Li, L., Xu, X. M., Liu, B., et al. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102645 · Cited by 31
Self-citationTargeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons
Bright, S. J., Flint, D. B., Martinus, D. K. J., Turner, B., Manandhar, M., Kacem, M. B., McFadden, C. H., Yap, T. A., Shaitelman, S. F., & Sawakuchi, G. O. (2022) · Radiation Research · doi:10.1667/rade-22-00040.1 · Cited by 31
“In addition to radiosensitization, ATR inhibition combined with radiation has been shown to augment immune activation (52, 53) and promote antitumor activity.”
BackgroundWang, L., Jiang, S., Yuan, Y., Duan, J., Mao, N., Hui, Z., Bai, R., Xie, T., & Ye, X. (2022) · Molecules · doi:10.3390/molecules27082491 · Cited by 29
The dual function of cGAS-STING signaling axis in liver diseases
Li, X., Qu, J., Zhang, Y.-H., & Liu, R. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01220-5 · Cited by 29
“The Hepa1-6 cell-induced HCC mice model treated with the above triple-therapy manifested smaller tumor volume than mice treated solely with the STING inhibitor C-176 [78].”
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
Zhang, T., Zheng, S., Yang, L., Li, X., Wu, J., Sun, Y., & Liu, G. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103112 · Cited by 30
Koch, M., Zdioruk, M. I., Nowicki, M. O., Griffith, A. M., Aguilar-Córdova, E., Aguilar, L. K., Guzik, B. W., Barone, F., Tak, P. P., Schregel, K., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.07.009 · Cited by 30
Bright, S. J., Manandhar, M., Flint, D. B., Kolachina, R., Kacem, M. B., Martinus, D. K. J., Turner, B., Qureshi, I., McFadden, C. H., Marinello, P. C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179599 · Cited by 30
“Our study used previously reported concentrations of AZD6738 in combination with radiation (5, 27, 28), which have been shown to reach levels of 10.1 μ g/mL in tumor tissue (60).”
BackgroundMethodInfluentialHeumann, T. R., & Azad, N. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09981-3 · Cited by 28
Mechanistic rationales for combining immunotherapy with radiotherapy
Chi, A., & Nguyen, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125905 · Cited by 29
Regulating the Expression of HIF-1α or lncRNA: Potential Directions for Cancer Therapy
Zhang, M., Zhang, Y., Ding, Y., Huang, J., Yao, J., Xie, Z., Lv, Y., & Zuo, J. (2022) · Cells · doi:10.3390/cells11182811 · Cited by 30
Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes
Mavroeidi, D., Georganta, A., Panagiotou, Ε., Syrigos, K., & Souliotis, V. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052767 · Cited by 27
“Indeed, combined treatment with radiotherapy and ATR inhibitor-induced type I/II IFN signaling and infiltration of CD8+ T-cells in a manner dependent on cGAS/STING [89–91].”
BackgroundImpact of radiation therapy on the immunological tumor microenvironment
Guilbaud, E., Naulin, F., Meziani, L., Deutsch, É., & Galluzzi, L. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.001 · Cited by 26
Zheng, Y., Liu, Y., Zhang, F., Chen, S., Chen, X., Zhang, M., Sun, M., Sun, Y., & Xing, L. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.005 · Cited by 25
“An increasing trend was observed for IFN-γ-producing T cells in tumors, but the percentage of spleen T cells that produced IFN-γ was not significantly changed, which may be due to the fact that T cells in the spleen could not be adequately exposed to tumor antigen.(28) Other cytotoxicity markers such as granzyme B, pe…”
BackgroundXie, Y., Liu, Y., Lin, M., Li, Z., Shen, Z., Yin, S., Zheng, Y., Zou, Y., Zhang, Y., Zhan, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.023 · Cited by 24
“Radiotherapy can increase the infiltration of CD8+ T cells in the tumor microenvironment [15], but the impact of combined ATM inhibitors on CD8+ T cells within the colorectal cancer microenvironment remains unclear.”
Goff, P. H., Bhakuni, R., Pulliam, T. H., Lee, J. H., Hall, E. T., & Nghiem, P. (2021) · Cancers · doi:10.3390/cancers13143415 · Cited by 25
Xie, Y., Liu, C., Zhang, Y., Li, A., Sun, C., Li, R., Xing, Y., Shi, M., & Wang, Q. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258817 · Cited by 24
Radiation therapy in the era of immune treatment for hepatocellular carcinoma
Chen, L., Zhang, R., Lin, Z., Tan, Q., Huang, Z., & Liang, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100079 · Cited by 25
“Another study showed that the ionizing radiation (IR)-induced DNA damage repair (DDR) inhibitor AZD6738 in combination with RT and ICIs in HCC led to stronger immunologic memory, lasting antitumor immunity than radioimmunotherapy, and the prevention of tumor recurrence in mouse models, which relied on the activation o…”
BackgroundTriple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape
Qiu, Y., Hu, X., Zeng, X., & Wang, H. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022153 · Cited by 23
Self-citationChen, W., Kang, Y., Sheng, W., Huang, Q., Cheng, J., Pei, S., & Meng, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331841 · Cited by 26
“These advancements in DNA repair-targeting drugs are increasingly playing a signi fi cant role in the fi eld of tumor therapy (39, 40).”
BackgroundWang, G., Shen, X., Jin, W., Song, C., Dong, M., Zhou, Z., & Wang, X. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06895-0 · Cited by 23
“These nude mice were accommodated in a sterile SPF-grade animal facility and underwent a one-week acclimatization period during which their health and condition were monitored [26].”
Feng, D., Kang, X., Wang, H., He, Z., Xu, H., Li, Y., Fan, A., Xu, H., Zhang, Y., Song, J., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123126 · Cited by 22
Self-citationMeyer, F., Engel, A. M., Krause, A. K., Wagner, T., Poole, L., Dubrovska, A., Peitzsch, C., Rothkamm, K., Petersen, C., & Borgmann, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.765284 · Cited by 23
“This is in line with other in vitro and in vivo studies showing a significantly increased the activation of the immune response, expression of inflammatory genes and the infiltration of CD8+ T-cells after combination of irradiation with ATR inhibition in comparison to irradiation alone (11, 57, 58).”
ResultInterplay between the DNA Damage Response and Immunotherapy Response in Cancer
Lee, E. C. Y., Kok, J. S.-T., Teh, B. T., & Lim, K. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113356 · Cited by 23
Patin, E. C., Nenclares, P., Hak, C. C. W., Dillon, M. T., Patrikeev, A., McLaughlin, M., Grove, L., Foo, S., Soliman, H., Barata, J. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51236-6 · Cited by 22
“Indeed, combining ATRi/RT with anti-PD-L1 blockade signi fi cantly improved tumour growth control and survival in mice 17,18 .”
Karukonda, P., Odhiambo, D. A., & Mowery, Y. M. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23384 · Cited by 22
“Another study investigated the role of triple therapy, showing that AZD6738 synergized with anti‐PD‐L1 antibody and radiotherapy to promote an antitumor immune response and prolong survival in mouse models of hepatocellular carcinoma.(38) Ap-”
BackgroundSugitani, N., Vendetti, F. P., Cipriano, A. J., Pandya, P., Deppas, J. J., Moiseeva, T. N., Schamus-Haynes, S., Wang, Y., Palmer, D., Osmanbeyoglu, H. U., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111371 · Cited by 22
“In addition, ATR inhibitor AZD6738 (ATRi) combines with radiation to generate CD8 + T cell-dependent responses in immunoproficient mouse models of cancer (Dillon et al., 2019; Sheng et al., 2020; Vendetti et al., 2018).”
Yin, Z., Zhang, H., Zhang, K., Yue, J., Tang, R., Wang, Y., Deng, Q., & Yu, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13801-0 · Cited by 21
“They can be rapidly differentiated into effector T cells following tumor antigens stimulation [41].”
When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity
Pan, D., Wang, Q., Shen, A., Qi, Z., Zheng, C., & Hu, B. (2024) · International Journal of Cancer · doi:10.1002/ijc.34954 · Cited by 22
Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated Tumors
Shim, Y. J. (2025) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2025.0017 · Cited by 20
“Preclinical studies have confirmed synergy with radiotherapy and programmed cell death ligand 1 blockade in ATM - or TP53 -deficient models [25].”
Classen, S., Petersen, C., & Borgmann, K. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02103-8 · Cited by 21
“This significantly improved the immunological microenvironment of the tumor [108].”
BackgroundMa, Y., Qi, Y., Zhou, Z., Yan, Y., Chang, J., Zhu, X., Han, J., Wu, H., Tao, Y., & Fan, F. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155171 · Cited by 20
Mariampillai, A. E., Hauge, S., Kongsrud, K., & Syljuåsen, R. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138920 · Cited by 19
“In a hepatocellular carcinoma model, the triple-treatment caused increased CD8 T cell infiltration, less regulatory T cells and increased immunological memory compared to after co-treatment with radiotherapy and anti-PDL1 (21).”
BackgroundWang, B., Hu, J. R., Zhang, J., & Zhao, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108646 · Cited by 19
Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors
Jeong, S., Chung, Y., Heo, S., & Myung, K. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf040 · Cited by 17
“Preclinical hepatocellular carcinoma models showed improved tumor control with anti-PD-L1 therapy, and in the ATLANTIS phase II study in PD-1–refractory melanoma, dur-valumab plus ceralasertib achieved objective responses in a subset of patients ( ∼ 10%–15%, NCT03780608) [ 106–108 ].”
Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment
Maresca, L., Stecca, B. A., & Carrassa, L. (2022) · Cells · doi:10.3390/cells11091466 · Cited by 17
Wang, S., Zheng, Q.-Y., Hong, W.-F., Tang, B., Hsu, S.-J., Zhang, Y., Zheng, X., Zeng, Z.-C., Gao, C., Ke, A., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110424 · Cited by 17
Micro-Nano Convergence-Driven Radiotheranostic Revolution in Hepatocellular Carcinoma
Peng, Y., Liu, H., Miao, M., Xu, C., Chen, S., Yan, K., Mu, J., Cheng, H., & Liu, G. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c05525 · Cited by 17
Xie, H., Wang, W., Qi, W.-C., Jin, W., & Xia, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661115 · Cited by 17
“The data suggest that DNA damage repair (DDR) deficiency promotes local antigen release, resulting in systemic antitumor immune responses (5).”
BackgroundYu, H., Wang, C., Ke, S., Bai, M., Xu, Y., Lu, S., Feng, Z., Qian, B., Xu, Y. M., Zhou, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892750 · Cited by 19
“Using GSEA, we also revealed that low CFHR4 expression was significantly associated with FCGR-activated reactions, the PLK1 pathway, reactant FCERI- June 2022 | Volume 13 | Article 892750 mediated MAPK activation, the ATR pathway, the MCM pathway, the cascade reactions of PI3K and FGFR1, reactantmediated MAPK activati…”
BackgroundInfluentialNew insights into T-cell exhaustion in liver cancer: from mechanism to therapy
Hao, L., Li, S., & Hu, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05083-5 · Cited by 17
Lewicky, J. D., Martel, A. L., Gupta, M. R., Roy, R., Rodriguez, G. M., Vanderhyden, B. C., & Le, H. (2023) · Cancers · doi:10.3390/cancers15164127 · Cited by 16
“showed that the ATR inhibitor ceralasertib (AZD6738) increased the degree of radiotherapyinduced CD8+ T cell infiltration and activation in a mouse xenograft model of hepatocellular carcinoma, while also decreasing the immunosuppressive effects of the radiation on numbers of intratumoral Tregs and exhausted T cells [1…”
BackgroundHu, S., Hui, Z., Duan, J., Garrido, C., Xie, T., & Ye, X. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2027911 · Cited by 16
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Seidel, P., Rubarth, A., Zodel, K., Peighambari, A., Neumann, F., Federkiel, Y., Huang, H., Hoefflin, R., Adlesic, M., Witt, C. C., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156087 · Cited by 16
Zhang, F., Zhou, K., Yuan, W., & Sun, K. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2276525 · Cited by 16
Dillon, M. T., Patin, E. C., Mohammed, K., Guevara, J., Smith, S. A., Dean, E. J., Soliman, H., Nenclares, P., Ryugenji, M., Northcote, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62249-0 · Cited by 15
“In preclinical models, increasesinin fl ammationafterATRi-RThavebeendemonstrated 4,5,16,17 .”
Kiesel, B. F., Guo, J., Parise, R. A., Venkataramanan, R., Clump, D. A., Bakkenist, C. J., & Beumer, J. H. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04388-x · Cited by 15
Chen, T., Tongpeng, S., Lu, Z., Topatana, W., Juengpanich, S., Li, S., Hu, J., Cao, J., Lee, C., Tian, Y., et al. (2022) · Aging and Cancer · doi:10.1002/aac2.12047 · Cited by 18
Yu, X., Zhu, L., Wang, T., Li, L., Liu, J., Che, G., & Zhou, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188910 · Cited by 15
Wang, S., Qi, Y., Zhao, R., Pan, Z., Li, B., Qiu, W., Zhao, S., Guo, X., Ni, S., Li, G., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae014 · Cited by 15
Rødland, G. E., Temelie, M., Mariampillai, A. E., Serban, A. M., Edin, N. F. J., Malinen, E., Lindbergsengen, L., Gilbert, A., Chevalier, F., Savu, D., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110669 · Cited by 15
Metadata
- Authors
- Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., Zhang, W., Sun, J., & Cao, C.
- Affiliations
- Nanfang Hospital (CN)
- Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
- Department of Stomatology, No 2 Hospital of Baoding, Baoding, Hebei, China
- Corresponding author
- Cao, Chuanhui
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-05
- Volume
- 8
- Issue
- 1
- Pages
- e000340
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7254123
- OpenAlex
- W3029836467
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 24 · 2025: 40 · 2024: 36 · 2023: 42 · 2022: 49 · 2021: 31 · 2020: 5
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81702390, 81903133)
- Guangzhou Science and Technology Program key projects (201906010087)
- Natural Science Foundation of Guangdong Province (2017A030310105, 2018A030313398)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- AZD6738, hepatocellular carcinoma, radioimmunotherapy, DNA repair inhibition, tumor immune microenvironment, immune checkpoint inhibitors, PD-L1 inhibitors, radiotherapy, cGAS-STING pathway, CD8+ T cells, regulatory T cells, T cell exhaustion, tumor-infiltrating lymphocytes, immunological memory, combination therapy, tumor recurrence
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Disease Models, Animal, Drug Synergism, Female, Carcinoma, Hepatocellular, Humans, Indoles, Liver Neoplasms, Morpholines, Pyrimidines, Sulfonamides, Sulfoxides, Lymphocytes, Tumor-Infiltrating, Radioimmunotherapy, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Tumor Microenvironment, Chemoradiotherapy, B7-H1 Antigen, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.